Mathiot C - Search Results

1

Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2.

Leger-Ravet MB, Mathiot C, Portier A, Brandely M, Galanaud P, Fridman WH, Emilie D. Leger-Ravet MB, et al. Among authors: mathiot c. Cancer Immunol Immunother. 1994 Jul;39(1):53-8. doi: 10.1007/BF01517181. Cancer Immunol Immunother. 1994. PMID: 8044827 Free PMC article. Clinical Trial.

2

[Treatment of metastatic malignant melanoma with interleukin-2].

Dorval T, Fridman WH, Mathiot C, Sastre X, Pouillart P. Dorval T, et al. Among authors: mathiot c. Bull Cancer. 1992;79(8):781-7. Bull Cancer. 1992. PMID: 1467601 French.

3

Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Toledano M, Mathiot C, Michon J, Andreu G, Lando D, Brandely M, Fridman WH. Toledano M, et al. Among authors: mathiot c. Cancer Immunol Immunother. 1989;30(1):57-64. doi: 10.1007/BF01665031. Cancer Immunol Immunother. 1989. PMID: 2513112 Free PMC article.

4

IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters.

Dorval T, Mathiot C, Chosidow O, Revuz J, Avril MF, Guillaume JC, Tursz T, Brandely M, Pouillart P, Fridman WH. Dorval T, et al. Among authors: mathiot c. Biotechnol Ther. 1992;3(1-2):63-79. Biotechnol Ther. 1992. PMID: 1305893 Clinical Trial.

5

Current status of interleukin-2 therapy in cancer.

Tartour E, Mathiot C, Fridman WH. Tartour E, et al. Among authors: mathiot c. Biomed Pharmacother. 1992;46(10):473-84. doi: 10.1016/0753-3322(92)90005-r. Biomed Pharmacother. 1992. PMID: 1306361 Review.

6

Lack of effect of tumour infiltrating lymphocytes in patients with metastatic melanoma who failed to respond to interleukin 2.

Dorval T, Mathiot C, Brandely M, Escande MC, Fridman WH, Pouillart P. Dorval T, et al. Among authors: mathiot c. Eur J Cancer. 1992;28(2-3):615-6. doi: 10.1016/s0959-8049(05)80107-8. Eur J Cancer. 1992. PMID: 1591084 No abstract available.

7

Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.

Farace F, Mathiot C, Brandely M, Tursz T, Dorval T, Pouillart P, Triebel F, Hercend T, Fridman WH. Farace F, et al. Among authors: mathiot c. Clin Exp Immunol. 1990 Nov;82(2):194-9. doi: 10.1111/j.1365-2249.1990.tb05426.x. Clin Exp Immunol. 1990. PMID: 2122928 Free PMC article.

8

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P, Fridman WH. Tartour E, et al. Among authors: mathiot c. Br J Cancer. 1994 May;69(5):911-3. doi: 10.1038/bjc.1994.175. Br J Cancer. 1994. PMID: 8180022 Free PMC article.

9

Interleukin-2 therapy for metastatic uveal melanoma.

Dorval T, Fridman WH, Mathiot C, Pouillart P. Dorval T, et al. Among authors: mathiot c. Eur J Cancer. 1992;28A(12):2087. doi: 10.1016/0959-8049(92)90266-5. Eur J Cancer. 1992. PMID: 1419309 Clinical Trial. No abstract available.

10

Prognostic value of cytokine and soluble Fc gamma receptor assays in oncology.

Tartour E, Pannetier C, Mathiot C, Teillaud JL, Sautès C, Kourilsky P, Fridman WH. Tartour E, et al. Among authors: mathiot c. Immunol Lett. 1995 Jan;44(2-3):145-8. doi: 10.1016/0165-2478(94)00206-7. Immunol Lett. 1995. PMID: 7797244

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters